Repligen Corporation (RGEN)
| Market Cap | 11.71B |
| Revenue (ttm) | 327.09M |
| Net Income (ttm) | 43.83M |
| Shares Out | 52.55M |
| EPS (ttm) | 0.83 |
| PE Ratio | 261.18 |
| Forward PE | 212.77 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $215.47 |
| Previous Close | $212.25 |
| Change ($) | 3.22 |
| Change (%) | 1.52% |
| Day's Open | 213.75 |
| Day's Range | 212.40 - 217.78 |
| Day's Volume | 417,738 |
| 52-Week Range | 84.96 - 217.78 |
The tailwinds behind the company's gains aren't going anywhere.
WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will prese...
The bioprocessing technology company gained momentum during the coronavirus pandemic.
Based on strong fundamentals, here we talk about four healthcare stocks to keep in your watchlist for 2021.
Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming releases.
Is (RGEN) Outperforming Other Medical Stocks This Year?
WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1....
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock a...
Repligen is a "pick-and-shovel" play in the bioprocessing industry. Repligen heavily invests in single-use products for use in downstream continuous manufacturing processes, which are two of t...
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common ...
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.
Is (RGEN) Outperforming Other Medical Stocks This Year?
Repligen (RGEN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
These top-ranked stocks are likely to beat on bottom line in their next releases.
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.
The bioprocessing technology company is having a great year.
Repligen stock jumped 9% on the heels of the report to a new 52-week high of $203.90 today. And Louis Navellier sees a lot more upside for the company.
Repligen Corporation's (RGEN) CEO Tony Hunt on Q3 2020 Results - Earnings Call Transcript
Repligen (RGEN) delivered earnings and revenue surprises of 42.86% and 8.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entere...
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST -
Stocks Rally As Trump Set To Leave Hospital; Repligen, United Rentals, Marvell Tech Break Out
Trumps scheduled to leave the hospital and stocks recover from Friday’s sell off. Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, i...
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Nav...
Repligen hasn't seen quite the same tailwind from COVID-19 as some of its larger, more diversified rivals, but pandemic-related product development is still adding about 10% to sales.
The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen Corporation (RGEN).
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Nasdaq Soars To New High In Heavy Volume
Stocks splits boosted shares of Tesla and Apple Monday, but several other stocks scored big gains.
These top-ranked stocks are likely to beat on their bottom line in the next releases.
Top Ranked Momentum Stocks to Buy for August 13th
The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript
Growth Stocks Lift Nasdaq To Another Day Of Outperformance
Earnings reports were in focus again, with Qorvo, Repligen and Teladoc making big moves
Repligen stock broke out Friday after the maker of products and services designed to speed development of coronavirus treatments posted an earnings beat and raised its 2020 outlook. The post I...
Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Repligen is building a base and near a possible buy range ahead of its next quarterly earnings report, expected on or around Jul. 30. The post Coronavirus Play Repligen Near Buy Zone With Earn...
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (RGEN) Outperforming Other Medical Stocks This Year?
Webcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT
Investors have come to value the company's resilience in an uncertain year.
In a low interest rate environment, acquisition targets in growth markets are likely to attract bidders.
Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high thro... [Read more...]
| Industry Medical Instruments & Supplies | Founded 1981 |
| CEO Anthony Hunt | Employees 761 |
| Stock Exchange NASDAQ | Ticker Symbol RGEN |
Financial Performance
In 2019, Repligen's revenue was $270.25 million, an increase of 39.28% compared to the previous year's $194.03 million. Earnings were $21.41 million, an increase of 28.85%.
Analyst Forecasts
According to 9 analysts, the average rating for Repligen stock is "Strong Buy." The 12-month stock price forecast is 211.50, which is a decrease of -1.84% from the latest price.